CHRU Nancy Brabois

The trials here

What the 4 trials at this site are about, from their registry records.

Conditions

• Acute myeloid leukaemia1 trial
• Gastric and oesophageal cancer1 trial
• Liver and biliary tract cancer1 trial
• Lung cancer1 trial

Phase

• Phase 22 trials
• Phase 2/31 trial
• Phase 31 trial

Status

• Recruiting2 trials
• Active, not recruiting1 trial
• Completed1 trial

Lead sponsor

• Federation Francophone de Cancerologie Digestive1 trial
• Fondation Franc.Cancerologie Digestive1 trial
• Intergroupe Francophone de Cancerologie Thoracique1 trial
• Kura Oncology, Inc.1 trial

Running trials

• Not yet recruiting

  PErioperative CISGEM + Rilvegostomig in High-Risk Resectable Intra Hepatic CholangioCarcinoma

  NCT07128290· Phase 2· Federation Francophone de Cancerologie Digestive· Source

• Recruiting

  Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML

  NCT07007312· Phase 3· Kura Oncology, Inc.· Source

• Recruiting

  De-escalation Immunotherapy mAintenance Duration Trial for Stage IV Lung Cancer Patients With Disease Control After Chemo-immunotherapy Induction

  NCT05255302· Phase 2/3· Intergroupe Francophone de Cancerologie Thoracique· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Acute myeloid leukaemia1 recruiting
• Lung cancer1 recruiting

Closed trials

• Completed

  PRODIGE 111 – DOMZIGAST A randomized phase II study evaluating FOLFIRI vs FOLFIRI plus Domvanalimab (anti-TIGIT) and Zimberelimab (anti-PD1) in patients with advanced gastric or gastro-oesophageal junction adenocarcinoma with progression during or after peri-operative chemotherapy.

  2024-519258-35-00· Phase 2· Fondation Franc.Cancerologie Digestive· Source